New HIV vaccine and antibody cocktail aims to free patients from daily meds

NCT ID NCT04983030

Completed Disease control Sponsor: Boris Juelg, MD PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a two-part vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) combined with three broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS) in 28 adults with HIV who were already on suppressive antiretroviral therapy (ART). The goal was to see if this combination could safely allow participants to stop ART and keep the virus under control. The trial focused on safety, immune response, and whether the virus stayed suppressed during a temporary treatment pause.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HIV vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) plus broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS)
What this could lead to: If successful, this approach could help people with HIV control the virus without needing daily antiretroviral therapy, potentially leading to long-term remission.
What could go wrong: This is an early-phase trial with only 28 participants, so results may not apply broadly. The treatment may not safely control the virus, and side effects like injection-site reactions or blood-clotting issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED IMMUNODEFICIENCY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease uterine carcinosarcoma viral sexually transmitted disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACQUIRED IMMUNODEFICIENCY SYNDROME HIV IMMUNOLOGIC DEFICIENCY SYNDROME, ACQUIRED RETROVIRIDAE INFECTIONS SEXUALLY TRANSMITTED DISEASES, VIRAL

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Orlando Immunology Center

Orlando, Florida, 32803, United States
UCLA CARE (Center for AIDs Research and Education)

Los Angeles, California, 90035, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Washington Positive Research

Seattle, Washington, 98104, United States
Washington University Clinical Trials Unit

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.